Gilead Sciences has once again extended its tender offer to acquire Arcellx.

Analysts have provided insights and conflicting sentiments on several healthcare companies, including Crinetics Pharmaceuticals, QuidelOrtho, Akebia Therapeutics, GE Healthcare Technologies, Arcellx Inc, and Pacira Pharmaceuticals.

Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its presence in the biotechnology sector.

Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.

Gilead Sciences has provided details on its deals with Tubulis, Ouro, and Arcellx, which are seen as pipeline catalysts, with further updates expected by 2026.

The president of Arcellx sold $10 million worth of shares following an acquisition announcement related to the company.

Shares of Arcellx experienced a substantial increase, rising almost 80% in a single day, with the article explaining the reasons behind this surge.

These are the stocks posting the largest moves in premarket trading.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.

Arcellx has completed an $80 million stock sale, which comes after a significant drop in its stock price and the emergence of a rival drug in the market.

The President of Arcellx has sold $10 million worth of company shares following an acquisition announcement.

Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.

Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion  Reuters

Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.